The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: A randomized pilot study

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  de Groot, Stefanie ^a   Vreeswijk, Maaike P G ^a   Welters, Marij J P ^a   Gravesteijn, Gido ^a   Boei, Jan J W A ^a   Jochems, Anouk ^a   Houtsma, Daniel ^b   Putter, Hein ^a   van der Hoeven, Jacobus J M ^a   Nortier, Johan W R ^a   Pijl, Hanno ^a   Kroep, Judith R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

Author keywords

Chemotherapy; DNA damage; Early stage breast cancer; Short term fasting; Toxicity

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA HISTONE H2AX; GRANISETRON; HISTONE H2AX; PEGFILGRASTIM; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; H2AFX PROTEIN, HUMAN; HISTONE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DIETARY REFERENCE INTAKE; DIZZINESS; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EARLY CANCER; ERYTHROCYTE COUNT; EYE DISEASE; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERSENSITIVITY; INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIC ENTEROCOLITIS; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PNEUMONIA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SHORT TERM FASTING; THERAPY EFFECT; THROMBOCYTE COUNT; TYPHLITIS; BREAST NEOPLASMS; CANCER GRADING; CLINICAL TRIAL; DEFICIENCY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MORTALITY; NEOADJUVANT THERAPY; PATHOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BREAST NEOPLASMS; DNA DAMAGE; FASTING; FEMALE; HISTONES; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PILOT PROJECTS; RECEPTOR, ERBB-2; TIME FACTORS; TREATMENT OUTCOME;

EID: 84946472104     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1663-5     Document Type: Article

References (50)

1. Sheldon WG, Bucci TJ, Hart RW, Turturro A. Age-related neoplasia in a lifetime study of ad libitum-fed and food-restricted B6C3F1 mice. Toxicol Pathol. 1995;23:458-76.
2. Mulrooney TJ, Marsh J, Urits I, Seyfried TN, Mukherjee P. Influence of caloric restriction on constitutive expression of NF-kappaB in an experimental mouse astrocytoma. PLoS One. 2011;6:e18085.
3. De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzua P, Vatner SF, Rabson AB. Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis. 2011;32:1381-7.
4. Weindruch R, Walford RL. Dietary restriction in mice beginning at 1year of age: effect on life-span and spontaneous cancer incidence. Science. 1982;215:1415-8.
5. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325:201-4.
6. Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell. 2008;7:681-7.
7. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346-53.
8. Walford RL, Mock D, Verdery R, MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J Gerontol A Biol Sci Med Sci. 2002;57:B211-24.
9. Doyle C, Kushi LH, Byers T, Courneya KS, Demark-Wahnefried W, Grant B, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 2006;56:323-53.
10. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4:124ra27.
11. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A. 2008;105:8215-20.
12. Safdie F, Brandhorst S, Wei M, Wang W, Lee C, Hwang S, et al. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One. 2012;7:e44603.
13. Laviano A, Rossi FF. Toxicity in chemotherapy--when less is more. N Engl J Med. 2012;366:2319-20.
14. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19:181-92.
15. Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. Science. 2010;328:321-6.
16. Bishop NA, Guarente L. Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet. 2007;8:835-44.
17. Maccario M, Aimaretti G, Grottoli S, Gauna C, Tassone F, Corneli G, et al. Effects of 36hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency. Int J Obes Relat Metab Disord. 2001;25:1233-9.
18. Wijngaarden MA, van der Zon GC, Willems van Dijk KW, Pijl H, Guigas B. Effects of prolonged fasting on AMPK signaling, gene expression and mitochondrial respiratory-chain content in skeletal muscle from lean and obese individuals. Am J Physiol Endocrinol Metab. 2013;304(9):E1012-21.
19. Bergman BC, Cornier MA, Horton TJ, Bessesen DH. Effects of fasting on insulin action and glucose kinetics in lean and obese men and women. Am J Physiol Endocrinol Metab. 2007;293:E1103-11.
20. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, et al. Fasting and cancer treatment in humans: a case series report. Aging (Albany NY). 2009;1:988-1007.
21. Kuo LJ, Yang LX. Gamma-H. In Vivo. 2008;22:305-9.
22. Rube CE, Grudzenski S, Kuhne M, Dong X, Rief N, Lobrich M, et al. DNA double-strand break repair of blood lymphocytes and normal tissues analysed in a preclinical mouse model: implications for radiosensitivity testing. Clin Cancer Res. 2008;14:6546-55.
23. Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 2004;279:2273-80.
24. Klokov D, MacPhail SM, Banath JP, Byrne JP, Olive PL. Phosphorylated histone H2AX in relation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol. 2006;80:223-9.
25. Redon CE, Dickey JS, Bonner WM, Sedelnikova OA. gamma-H2AX as a biomarker of DNA damage induced by ionizing radiation in human peripheral blood lymphocytes and artificial skin. Adv Space Res. 2009;43:1171-8.
26. Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys. 2004;58:331-5.
27. Li P, Du CR, Xu WC, Shi ZL, Zhang Q, Li ZB, et al. Correlation of dynamic changes in gamma-H2AX expression in peripheral blood lymphocytes from head and neck cancer patients with radiation-induced oral mucositis. Radiat Oncol. 2013;8:155.
28. Fleckenstein J, Kuhne M, Seegmuller K, Derschang S, Melchior P, Graber S, et al. The impact of individual in vivo repair of DNA double-strand breaks on oral mucositis in adjuvant radiotherapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81:1465-72.
29. Rube CE, Fricke A, Schneider R, Simon K, Kuhne M, Fleckenstein J, et al. DNA repair alterations in children with pediatric malignancies: novel opportunities to identify patients at risk for high-grade toxicities. Int J Radiat Oncol Biol Phys. 2010;78:359-69.
30. Bourton EC, Plowman PN, Smith D, Arlett CF, Parris CN. Prolonged expression of the gamma-H2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radiotherapy treatment. Int J Cancer. 2011;129:2928-34.
31. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf Internet 2015.
32. Hatam N, Ahmadloo N, Ahmad Kia DA, Bastani P, Askarian M. Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil). Arch Gynecol Obstet. 2011;284:215-20.
33. von Minckwitz G, Kummel S, du Bois A, Eiermann W, Eidtmann H, Gerber B, et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292-8.
34. Charehbili A, van de Ven S, Smit VT, Kranenbarg EM, Hamdy NA, Putter H, et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2 negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Ann Oncol. 2014;25(5):998-1004.
35. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-49.
36. Kim HJ, McGuire DB, Tulman L, Barsevick AM. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs. 2005;28:270-82.
37. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15:80-101.
38. Thomas A, Rajan A, Szabo E, Tomita Y, Carter CA, Scepura B, et al. A Phase I/II trial of belinostat in combination with cisplatin, doxorubicin and cyclophosphamide in thymic epithelial tumors: a clinical and translational study. Clin Cancer Res. 2014;20(21):5392-402.
39. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O, et al. Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol. 2008;20:504-11.
40. Grill V, Pigon J, Hartling SG, Binder C, Efendic S. Effects of dexamethasone on glucose-induced insulin and proinsulin release in low and high insulin responders. Metabolism. 1990;39:251-8.
41. Hickish T, Astras G, Thomas P, Penfold S, Purandare L, Hickish TF, et al. Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst. 2009;101:537.
42. Matsumoto K, Yamasaki H, Akazawa S, Sakamaki H, Ishibashi M, Abiru N, et al. High-dose but not low-dose dexamethasone impairs glucose tolerance by inducing compensatory failure of pancreatic beta-cells in normal men. J Clin Endocrinol Metab. 1996;81:2621-6.
43. Sanofi-Aventis. Taxotere (docetaxel) package insert. Bridgewater, NJ: 2007.
44. Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 2011;30:3305-16.
45. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251-62.
46. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274-93.
47. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21-35.
48. Scarpato R, Castagna S, Aliotta R, Azzara A, Ghetti F, Filomeni E, et al. Kinetics of nuclear phosphorylation (gamma-H2AX) in human lymphocytes treated in vitro with UVB, bleomycin and mitomycin C. Mutagenesis. 2013;28:465-73.
49. Snel M, Wijngaarden MA, Bizino MB, van der Grond J, Teeuwisse WM, van Buchem MA, et al. Food cues do not modulate the neuroendocrine response to a prolonged fast in healthy men. Neuroendocrinology. 2012;96:285-93.
50. Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and health span. Cell Metab. 2015;22:86-99.